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Abstract
BACKGROUND & AIMS—Gastric cancer (GC) is a heterogeneous disease comprising multiple
subtypes that each have distinct biological properties and effects in patients. We sought to identify
new, intrinsic subtypes of GC by gene expression analysis of a large panel of GC cell lines. We
tested if these subtypes might be associated with differences patient survival times and responses
to various standard-of-care cytotoxic drugs.
METHODS—We analyzed gene expression profiles for 37 GC cell lines to identify intrinsic GC
subtypes. These subtypes were validated in primary tumors from 521 patients in 4 independent
cohorts, where the subtypes were determined by either expression profiling or subtype-specific
immunohistochemical markers (LGALS4, CDH17). In vitro sensitivity to 3 chemotherapy drugs
(5-FU, cisplatin, oxaliplatin) was also assessed.
RESULTS—Unsupervised cell line analysis identified 2 major intrinsic genomic subtypes (G-
INT and G-DIF), that had distinct patterns of gene expression. The intrinsic subtypes, but not
subtypes based on Lauren’s histopathologic classification, were prognostic of survival, based on
univariate and multivariate analysis in multiple patient cohorts. The G-INT cell lines were
significantly more sensitive to 5-FU and oxaliplatin, but more resistant to cisplatin, than the G-
DIF cell lines. In patients, intrinsic subtypes were associated with survival time following
adjuvant, 5-FU based therapy.
CONCLUSIONS—Intrinsic subtypes of GC, based on distinct patterns of expression, are
associated with patient survival and response to chemotherapy. Classification of GC based on
intrinsic subtypes might be used to determine prognosis and customize therapy.
Keywords
Microarray analysis; pharmacogenomics; mRNA; stomach; carcinogenesis
Introduction
Gastric adenocarcinoma (gastric cancer, GC) is the second leading cause of global cancer
mortality and 4th most common cancer worldwide1. Most GC patients present with late stage
disease with an overall 5-year survival of about 20%2. A wealth of clinical, molecular, and
pathological data suggests that GC is a heterogeneous disease. Objective response rates to
conventional chemotherapeutic regimens range from 20–40%3, indicating that individual
GCs can exhibit a range of responses when treated identically. Canonical oncogenic
pathways such as E2F, K-RAS, p53, and Wnt/β-catenin signalling are also known to be
deregulated with varying frequencies in GC4, 5, suggesting a high degree of molecular
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heterogeneity. However, despite evidence that GCs can exhibit striking inter-individual
differences in disease aggressiveness6, histopathologic features7, and responses to therapy8,
most GC patients today are managed alike with a “one size fits all” approach resulting in
markedly diverse clinical outcomes. Approaches capable of classifying heterogeneous
populations of GC patients into biologically and clinically homogenous subgroups are thus
urgently required, such that GC patient prognoses can be accurately predicted, and clinical
decisions made based on the underlying biology of each subgroup.
Reflecting this urgency, several classification systems for GC have been reported over the
decades. In 1965, Lauren described two main subtypes of GC, intestinal and diffuse, on the
basis of microscopic features observed in gastric tumors7. Since then, several other GC
histopathological classifications have since been developed, such as the WHO9, Ming10, and
Goseki11 systems, and more recently, molecular classifications based on
immunohistochemistry, gene expression profiles12–15, and proteomic technologies16.
However, to date, none of these GC classification systems been shown to provide reliable
independent prognostic information, nor have they been able to suggest specific treatment
options for patients.
Most previously-described GC classification systems have principally focused on the
characterization of primary tumors, which are known to contain many distinct cell types
including tumor cells, fibroblastic/desmoplastic stroma, blood vessels, and immune cells.
Given this high level of tissue complexity, we reasoned that subtle variations in these
diverse cell types, both across and within-tumors, could cause differences in interpretation
between observers, and ultimately pose difficulties for standardization across different
centres. In this study, we pursued an alternative strategy where we initially focused not on
primary GCs, but on a diverse panel of GC cell lines. We hypothesized that since cancer cell
lines are devoid of other cell types besides cancer cells, any genomic differences detected in
cell lines should be by nature tumor-centric and thereby “intrinsic” to the underlying biology
of the GC cancer cell. Investigating a large panel of GC cell lines, we identified a genomic
expression signature clearly defining two major intrinsic subgroups of GC. Importantly, we
validated these intrinsic subgroups in primary tumors from 4 independent GC cohorts. The,
intrinsic subtypes proved capable of providing independent prognostic information. In vitro
and in vivo evidence also suggests that GCs belonging to different intrinsic subtypes may
respond differently to various standard-of-care chemotherapies.
MATERIALS AND METHODS
GC Cell Lines
GC cell lines were obtained from commercial sources or collaborators and cultured as
recommended (Supplementary Info). Cell proliferation assays were performed using a
tetrazolium compound-based colorimetric method (Supplementary Methods).
Patient Cohorts and Clinical Characteristics
Four independent patient cohorts were analyzed (n=521). Cohort 1 (SG): 200 patients,
National Cancer Centre Singapore, Singapore; Cohort 2 (AU): 70 patients, Peter MacCallum
Cancer Centre, Australia; Cohort 3 (YG): 65 patients, Yonsei University, South Korea;
Cohort 4 (TMA): 186 patients, National Healthcare Group, Singapore. Primary tumors were
collected from institutional tissue repositories and pathology archives with approvals from
Research Ethics Review Committees and signed patient informed consent. There was no
pre-specified sample size calculation since this is a hypothesis generating discovery study.
Clinical characteristics of the four cohorts are in accordance with REMARK guidelines17
and presented in Table 1. Clinical information was available for all patients except 3 patients
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in the SG cohort. Cohorts 1–3 (SG/AU/YG) comprise gene expression profiles of primary
GCs, while cohort 4 (TMA) comprises tumor sections on a tissue microarray.
Gene Expression Profiling (GC Cell lines and Primary Tumors)
GC cell lines and patient cohorts 1 and 2 were profiled using Affymetrix Human Genome
U133 plus Genechips (HG-U133 Plus 2.0, Affymetrix). Patient cohort 3 was profiled using
Illumina Human-6 v2 Expression Beadchips. Primary microarray data is available in the
GEO database (GSE 15460 and GSE13861).
Histology and Immunohistochemistry
Two independent pathologists (LKH, WWK) performed central pathologic review on cohort
1 samples blinded to the genomic classification. Immunohistochemical studies using
LGALS4 and CDH17 antibodies were performed on a tissue microarray of 186 GC patients
(cohort 4), and staining intensities determined by a pathologist blinded to the clinical data
(MST). Photomicrographs, details of staining patterns and grading scales are provided in the
Supplementary Information.
Bioinformatics and Statistical Analysis
Bioinformatic analyses were performed using R. Raw affymetrix datasets were preprocessed
with quantile normalization using RMA (package Affy). We filtered the Gastric cancer cell
line using the nsFilter function from the Genefilter package on Bioconductor. The R
package LIMMA was used for feature selection. Enrichment of functional annotations in the
gene expression data were performed using EASE software
(http://apps1.niaid.nih.gov/david/). Statistical significance was determined using the Fisher
exact score and EASE score. For patient cohorts, preprocessing of cohort 1 and 2
(Affymetrix) was performed with Refplus while preprocessing of cohort 3 (Illumina) was
performed with quantile normalization and the average signal intensity used for
summarization. Nearest Template Prediction18,19 was performed using Genepattern20. The
R package e1071 was used for support vector machine (SVM) learning and classification.
Correlation with clinico-pathologic parameters and survival analysis were performed using
SPSS software (version 16, Chicago). Survival curves were estimated using the Kaplan-
Meier method and the duration of survival was measured from the date of surgery to date of
death or last follow-up visit. Cancer-specific survival (CSS) was used as the outcome metric,
with deaths due to cancer was regarded as an event. Patients who are still alive, died from
other causes or lost to follow-up at time of analysis were censored at their last date of follow
up. Univariable and multivariable survival analyses were performed using the Cox
proportional hazards regression model. The test of interaction between the genomic subtypes
and therapy was performed with the null hypothesis of treatment equivalence within the
subtypes and the alternative hypothesis was of differential treatment efficacy in the
subtypes21. Two-sided p-values less than 0.05 were considered statistically significant.
Further details of bioinformatics and statistical analyses are provided in the Supplementary
Information.
RESULTS
Genomic Analysis of GC Cell Lines Reveals Two Major Intrinsic Subclasses
We performed gene expression profiling for a panel of 37 GC cell lines. To identify
pervasive and thereby “intrinsic” gene expression differences across the cell lines, we
analyzed the expression data using four different unsupervised and unbiased clustering
techniques (hierarchical clustering, silhouette plot (SP) analysis22, nonnegative matrix
factorization (NMF)23, and principal components analysis (PCA)). Two major intrinsic
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subtypes were identified by hierarchical clustering (Figure 1A). The robustness of the
subtypes was further verified by SP, NMF, and PCA analysis (Figure 1B and Supplementary
Figure S1). For reasons that will become apparent in later sections, we will henceforth refer
to these two intrinsic subtypes as Genomic intestinal (G-INT) and Genomic Diffuse (G-
DIF).
The Intrinsic Subtypes are Associated with Highly Distinctive Gene Expression Patterns
To analyze gene expression differences between the intrinsic subtypes, we used LIMMA
(Linear models for microarray data)24, a modified t-test incorporating the Benjamini
Hochberg multiple correction technique. We identified a genomic signature of 171 genes
distinguishing the G-INT and G-DIF intrinsic subtypes (FDR<0.002; Figure 1C and
Supplementary Table S1). We attempted to refine this signature by searching for potentially
redundant features among the 171 gene set. Comparing the correlation coefficients of the
171 genes to one another, we found that only 2 of the 171 genes exceeded a pre-defined
correlation threshold of 0.88. Given this lack of redundancy, we performed further analysis
using the entire 171 gene set. Using Expression Analysis Systematic Explorer (EASE)
(http://david.abcc.ncifcrf.gov/ease/ease.jsp), we identified enriched biological themes within
genes expressed in either subtype Genes up-regulated in the G-INT subtype were related to
carbohydrate and protein metabolism (FUT2) and cell adhesion (LGALS4, CDH17), while
cell proliferation (AURKB) and fatty acid metabolism (ELOVL5) functional annotations
were enriched in the G-DIF subtype (within system FDR < 0.01, Supplementary Methods
and Supplementary Table S2). The two intrinsic subtypes, G-INT and G-DIF, are thus
associated with highly distinctive gene expression patterns and biological pathways.
The Intrinsic Subtypes are Recurrently Observed in Primary Tumors
We mapped the intrinsic 171-gene genomic signature onto primary tumors in two
independent cohorts of GC patients (SG and AU), collectively totaling 270 patients. We
used 2 classification algorithms (Nearest Template Prediction and a support vector machine
classifier). Concordance between the 2 classification systems (SVM and NTP) was 94–96%
in the SG and AU cohorts with 88% of samples identified by NTP at an FDR of < 0.05.
These results suggest the 171 gene set can robustly classify primary tumors into G-INT and
G-DIF sub-classes. Due to its methodological simplicity and applicability to single samples
without requiring a corresponding training dataset19, the NTP classifications were used for
subsequent analyses. Specifically, 114 samples in the SG cohort and 38 samples in the AU
cohort were classified as G-INT (Figures 2A&B) (Supplementary Table S3).
The Intrinsic Subtypes are Partially Associated with Lauren’s Histopathologic
Classification
We next investigated their associations with clinical-pathologic parameters. The intrinsic
subtypes were found to be significantly associated with Lauren’s intestinal and diffuse
subtypes respectively in the SG (p=0.002) and AU cohorts (p=0.003), hence their name (G-
INT and G-DIF). Besides Lauren’s, the intrinsic subtypes were also related to tumor grade
(Supplementary Table S3).
Although we named the intrinsic subtypes G-INT and G-DIF due to their associations with
Lauren’s histopathology, it is worth noting that the overall concordance between the
intrinsic genomic subtypes and Lauren’s histopathology was only 64%. Thus, the two
classifications should more appropriately be regarded as related but distinct. Specifically, 91
of 134 Lauren’s intestinal cases were classified at G-INT, and 64 of 106 Lauren’s diffuse
cases were classified as G-DIF (Figures 2A&B). These discrepancies are unlikely to be due
to inter-pathologist differences alone, as pathologic review in the SG cohort had been
performed by 2 independent pathologists blinded to the genomic classification
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(Representative H&E slides of discordant tumors are also presented in figures 2C & 2D).
Rather, it is possible that the intrinsic genomic signature may capture salient features of the
tumor that are less obvious to discern by light microscopy.
The Intrinsic Subtypes are Independently Prognostic of Patient Survival
We next asked if the intrinsic subtypes could be used to define patient subgroups exhibiting
differences in survival outcomes. Using cancer-specific survival as the outcome metric,
patients with G-DIF cancers had worse survival outcomes compared to patients with G-INT
tumors in the SG and AU cohorts (cohort 1: HR 1.78, 95%CI: 1.19–2.64, p=0.004; cohort 2:
HR 1.73, 95%CI: 0.92–3.26, p=0.09) and also in a combined analysis (HR: 1.79, 95% CI:
1.28–2.51, p=0.001, Figure 3A). In contrast, Lauren’s classification was not prognostic
(p=0.23). Further supporting the prognostic relevance of the intrinsic subtypes, in discordant
cases, patients with G-INT but diffuse type cancers exhibited superior survival compared to
patients with G-DIF but intestinal type cancers (HR 1.83, 95%CI: 1.02–3.30, p=0.04, Figure
3B).
In a multivariate analysis (Table 2), the intrinsic subtypes remained prognostic (p<0.001)
even after accounting for other interacting factors such as Lauren’s classes and grade. The
intrinsic subtypes were also prognostic after accounting for other variables that were also
prognostic in univariate analysis (stage, margin status and gender) (p=0.005).
The Intrinsic Subtypes are Prognostic in an Independent Patient Cohort Profiled by a
Different Microarray Platform
To further determine the general applicability of the intrinsic subclasses, we then applied the
intrinsic genomic signature onto a third GC patient cohort (YG) profiled on a different
microarray platform (Illumina Human-6 v2 Expression Beadchip). Of the 65 patients, 35
were classified as G-INT by NTP (heatmap provided in Supplementary Figure S3A). Similar
to the SG and AU cohorts, patients with G-INT tumors had superior overall survival
compared to patients with G-DIF tumors in the YG cohort (HR 3.3, 95%CI: 1.03–10.53,
p=0.04) (Supplementary Figure S3B), while Lauren’s classes was not prognostic (p=0.23).
G-INT Patients Identified by Immunohistochemical Markers Exhibit Improved Survival
Outcomes
To assess if a panel of immunohistochemical markers might also be used to identify the
intrinsic subtypes and its relation to survival outcomes, we then analyzed an independent
tissue microarray (TMA) cohort (cohort 4) of 186 GC patients. We selected 2 G-INT
markers (LGALS4 and CDH17) meeting the criteria of high gene expression in G-INT cell
lines and tumors, and for which commercial immunohistochemical markers were available.
We classified the TMA tumors based on their intensity of LGALS4 and CDH17 staining
(CDH17 (> 1+) and LGALS4 (>2+)), using intensity cutoffs determined by a pathologist
blinded to the clinical data (see Supplementary Information). To confidently distinguish
between G-INT and G-DIF cancers, we specifically compared the 2-marker positive group
(G-INT) to the 2-marker negative group (G-DIF). Among the 186 tumors, 75 were classified
as G-INT (both markers positive), 44 as G-DIF (neither marker positive) and 67 were
equivocal (one marker positive). Patients with G-DIF tumors classified by IHC exhibited
worse outcomes than G-INT tumors classified by IHC (Hazard ratio, adjusted for stage:
1.95, 95%CI: 1.13–3.38, p=0.02) (Supplementary Figure S4), while Lauren was once again
not prognostic (p=0.33).
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The Intrinsic Subtypes Exhibit Distinct in vitro Responses to Chemotherapy
Of the 37 cell lines, 28 cell lines (11 G-INT and 17 G-DIF) had growth characteristics
suitable for in vitro drug sensitivity testing (see Supplementary Methods). 5-FU, oxaliplatin
and cisplatin are drugs presently employed in the adjuvant and 1st line palliative treatment of
GC. We treated the 28 cell lines with increasing concentrations of these drugs. G-INT cell
lines were significantly more sensitive to 5-FU (p=0.04) and oxaliplatin (p=0.02) in vitro,
while G-DIF cell lines were more sensitive to cisplatin (p=0.03) (Figure 4, see legend for
mean drug concentrations). The in vitro dosages used are comparable to therapeutic ranges
observed in human patients based on pharmacokinetic analysis25–27 (grey lines in Figure 4).
These results point to differential in vitro sensitivities of G-INT cell lines to 5-FU and
oxaliplatin, and G-DIF cell lines to cisplatin.
G-INT Patients may Derive Differential Benefit from 5-FU Treatment
Information regarding use of adjuvant 5 Fluorouracil chemoradiation were available from 2
gene expression cohorts (1 &2) and the TMA cohort (cohort 4). Decisions regarding
adjuvant therapy in these cohorts were based upon existing knowledge at the point of
diagnosis, patient’s general health status, risk factors for relapse especially disease stage,
treatment related toxicities and patient preference.
Patients with advanced stage disease were more likely to receive adjuvant treatment
(p=0.03), however no significant differences were observed in prescribing 5-FU therapy
between the intrinsic subtypes either across all stages (p=0.27) or within each stage (p~0.4–
0.8) (Supplementary Table S3). We performed a statistical test for interaction that was
specifically adjusted for stage, to evaluate if the intrinsic subtypes might exhibit differential
benefit with 5-FU chemoradiation in our patient cohorts.
We observed a significant interaction between the intrinsic subtypes and benefit with 5-FU
based chemoradiation (Table 3), suggesting that patients with G-INT tumors may derive
differential benefit from adjuvant 5-FU based therapy. Specifically, the test for interaction
by Cox proportional hazards regression was p=0.002 (combined analysis), gene expression
(p=0.03) and TMA cohorts (p=0.02). The stage adjusted hazard ratio of death due to cancer
for surgery alone compared to adjuvant 5-FU therapy was 1.68 (p=0.06 for G-INT tumors
and 0.90 (p=0.67) for G-DIF tumors. Table 3 presents the interactions for the combined
analysis, while the gene expression and TMA cohorts are separately presented in
Supplementary Table 4.
DISCUSSION
In this study, we report the discovery of two genomic subtypes of GC using profiles initially
derived from GC cell lines. Since cancer cell lines are devoid of stroma, vasculature and
immune cells, we reasoned that comparing signatures between cell lines would be more
likely to reflect intrinsic differences between tumor cells, minimizing potentially
confounding effects from neighboring non-cancer tissues. The validity of the cell line based
approach is supported by similar studies in other solid tumors28, 29, where major patterns of
tumor heterogeneity have also been shown to be recapitulated by cell lines. We
acknowledge that this approach does have caveats - for example, it may miss rare subtypes
represented by only one or two lines, or subtypes for which it is difficult to derive
immortalized cell lines. The use of cell lines is also unlikely to fully recapitulate the biology
of tumor/microenvironment interactions, which can also influence disease prognosis and
treatment response. Nevertheless, we believe the intrinsic subtypes discovered in this study
represents an important first step in establishing a basic foundational taxonomy of GC, one
to which additional layers of genomic complexity can be subsequently added.
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One notable aspect of our study was that unlike previous comparative molecular studies for
GC30, 31, we chose to use unsupervised approaches for subclass discovery. We did so
because a) the major distinctions in the molecular heterogeneity of GC might be unrelated to
presently known classification systems or phenotypes, and b) using current classification
systems, reproducibility among pathologists is only about 70%32, 33 and we were concerned
that this lack of inter-observer concordance might compromise supervised analysis. Testing
several different prediction algorithms, we confirmed that the intrinsic subtypes exhibited
stable and reproducible classification performance in cell lines and primary tumors, thus
demonstrating that the subtypes are statistically robust. Using a strict filtering criteria
(FDR<0.002), we then identified a genomic classifier of 171 genes exhibiting differential
regulation between the subtypes. Biological curation of the classifier confirmed that the
intrinsic subtypes are associated with very different gene expression features, cellular
processes and biological pathways. Taken collectively, these finding are consistent with the
intrinsic subtypes being very distinct and possibly representing distinct lineages.
The clinical relevance of the intrinsic subclasses is supported by the finding that it can act as
an independent predictor of clinical survival in multiple patient cohorts, even after
controlling for tumor stage. In this regard, it is interesting to contrast the intrinsic subclasses
against Lauren’s histological subtypes (intestinal and diffuse), to which the intrinsic classes
are partially associated. Intestinal cancers are classically characterized by glandular
differentiation on a background of gastric atrophy or intestinal metaplasia, while diffuse
cancers typically appear as rows of single mononuclear “signet ring” cells with little cell
adhesion. These apparently distinct features, however, are not always discernable in clinical
samples where inter-observer variation and unclassifiable or “mixed” subtypes are not
uncommonly reported. In our study, patients stratified by Lauren’s histopathology did not
exhibit significantly different survival outcomes, while patients discordant between the
intrinsic subclasses and Lauren’s exhibited survival patterns that support the intrinsic
genomic taxonomy. Our data thus suggests that the intrinsic subclasses can provide
information about the predominant lineage in GC samples that may not be precisely
distinguished by morphology, and that this information is clinically relevant.
Besides gene expression, we also employed two genes in the classifier (LGALS4 and L1-
Cadherin (CDH17)) as immunohistochemical markers for the G-INT intrinsic subtype.
LGALS4 and CDH17 have been previously reported to be differentially regulated across
subsets of gastric tumors14 and cell line34, and expressed in intestinal metaplasia35, 36.
CDH17 was recently reported as a prognostic factor in early-stage GC37, a marker of poor
prognosis in another study36, and a potential therapeutic target in experimental models38. In
our study, we specifically chose to compare the 2-marker positive group to the 2-marker
negative group to confidently distinguish between the G-INT and G-DIF cancers.
Interestingly, we have also observed that the one-third of 1-marker positive patients also
appeared to exhibit an improved survival trend compared to the 2-marker negative group
(CDH17, p=0.08 adjusted for stage; LGALS4, p=0.07 adjusted for stage). This result
suggests that some of the 1-marker positive cancers may also be G-INT cancers as well
(Supplementary Figure S4). At this stage, it is likely premature to definitely conclude that
LGALS4 and CDH17 necessarily represent the best markers for the G-INT subtype.
Identifying the optimal combination of immunohistochemical markers to distinguish
between the intrinsic subtypes should thus be a focus for future research.
In vitro, G-INT lines were more sensitive to 5-FU and oxaliplatin than G-DIF cell lines, but
were also more resistant to cisplatin. Although the absolute magnitude of these in vitro
differential sensitivities appears modest (3–5 fold), these differences could still prove
clinically meaningful given the relatively small therapeutic windows associated with
cytotoxic chemotherapy. Indeed, supporting the clinical relevance of these differences, we
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observed a significant interaction between the intrinsic subtypes and differential benefit
from adjuvant 5-FU therapy in retrospective patient cohorts (Table 3 and Supplementary
Table S4). These findings suggest that in addition to patient prognosis, the intrinsic subtypes
could potentially be used to guide treatment selection. However, we also emphasize that our
results at this stage should be interpreted in the context of an early discovery study,
requiring further validation efforts. For example, while we observed a trend of stage-
adjusted survival benefit in G-INT patients due to 5-FU adjuvant therapy, this benefit was
not statistically significant relative to surgery alone (Table 3 (combined, p=0.06) and Supp
Table S4 (gene expression, p=0.18; TMA, p=0.11). There may be multiple reasons for this –
compared to large Phase III trials such as INT-011639, which evaluated adjuvant 5-FU based
chemoradiation in GC, our patient cohorts are smaller in size, non-randomized, and being
retrospective in nature, quality of surgery and treatment regimens were also not strictly
enforced. As such, the interaction of intrinsic subclass with treatment response should
definitely be further validated in additional studies (see below). Nevertheless, given the
association the intrinsic subtypes with Lauren’s, it is worth noting that in INT-011640, a ten-
year update subgroup analyses revealed that all GC subsets benefited from 5-FU therapy
except for cases with diffuse histology. Moreover, in JCOG 991241 which established S-1
monotherapy as a first-line palliative chemotherapy option in Japan, benefit of irinotecan/
cisplatin over 5-FU based monotherapy was observed in diffuse but not intestinal GCs. Our
findings in this study are thus consistent with exploratory subgroup analysis of these two
large GC clinical trials.
Our hypothesis-generating study requires further validation studies. Most immediately, the
interaction between the intrinsic subtypes and treatment outcomes will be retrospectively
validated in larger patient cohorts including tissue from a randomized phase 3 Japanese trial
in the first line palliative treatment of advanced gastric cancer (PI: Akira Tsuburaya). Future
prospective research efforts will focus on validating the predictive value of the GC intrinsic
subclasses in the metastatic setting. In most countries, combination therapy with a
fluropyrimidine/platinum combination therapy with or without epirubicin remains standard
first line palliative chemotherapy(3). We have thus initiated a phase 2 study, Genomic
Guided Gastric cancer (3G) trial with mandatory pre-treated tumor biopsies from which
patients will be allocated to S1/oxaliplatin or S1/cisplatin based upon their genomic profiles
(NCT01100801, http://clinicaltrialsfeeds.org).
In conclusion, the quest for a clinically meaningful GC taxonomy has motivated several
attempts to classify GC on the basis of clinical, histologic, and molecular features. With the
exception of tumor stage however, few previously-proposed classification strategies have
been shown to provide additional prognostic or predictive value. It is possible that the
intrinsic subtypes reported here in this study may represent a promising step in
establishment of a clinically relevant genomic taxonomy of GC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Unsupervised clustering of GCCLs reveals 2 major intrinsic subtypes
(A) Hierarchical dendrogram depicting clustering of 37 GCCLs into G-INT (blue) and G-
DIF (red); height: squared euclidean distances between cluster means. (B) Silhouette widths
of individual cell lines when classified in 2 clusters. Silhouette width: a measure for each
sample of membership of within it s own class against that of another class. (C) heat map of
expression of 171 genes arranged by hierarchal clustering of cell lines (columns) and
expression difference for each gene between G-INT and G-DIF as measured by the t-test
statistic (rows).
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Figure 2. Associations of intrinsic subtypes with Lauren’s classification in primary GCs
Heat map of gene expression in (A) SG and (B) AU cohorts arranged by strength of
association (columns) and expression difference for each gene between G-INT and G-DIF as
measured by the t-test statistic (rows). 1st row label: Laurens class; light blue: intestinal,
brown: diffuse, white: mixed. 2nd row label: Intrinsic classes: blue: G-INT, red: G-DIF. C.
Representative H&E of (C) G-DIF/intestinal cancer and (D) G-INT/Diffuse cancer.
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Figure 3. Intrinsic genomic subclasses are prognostic
Kaplan-Meier plots of survival in (A) all patients (HR: 1.79, 95% CI: 1.28–2.51, p=0.001)
and (B) when the intrinsic classification and Lauren’s classes are discordant (HR 1.83,
95%CI: 1.02–3.30, p=0.04).
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Figure 4. In vitro chemosensitivity of G-INT and G-DIF cell lines
GI-50 values of 11 G-INT and 17 G-DIF cell lines upon treatment with 5-FU, oxaliplatin
and cisplatin. GI-50s refer to the drug concentration at which 50% growth inhibition is
achieved. (y-axis: GI-50 enumerated in negative log10). The horizontal grey lines represent
the therapeutic concentration patients are exposed to based on pharmacokinetic data25–27.
Mean GI-50 concentrations for G-INT and G-DIF cell lines respectively: 5FU: 5.20 μM,
23.22 μM; Cisplatin: 38.61 μM, 13.35 μM; Oxaliplatin: 1.33 μM, 5.49 μM.
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Table 2
Multivariable Cox proportional hazards models
Model (1) incorporates G-INT/G-DIF classes together with Lauren’s classes and histological grade which
were found to be associated with G-INT/G-DIF subtypes. Patients with mixed histology were excluded from
Model (1), Model (2) incorporates all variables found to be prognostic on univariate analysis. Statistically
significant results are in bold.
Model (1): Factors interacting with G-INT/G-DIF subtypes
Univariate, HR (95% CI), p value Multivariable, HR (95% CI), p value
G-INT/G-DIF G-INT 1.00 1.00
G-DIF 1.95 (1.36–2.78), p<0.001 1.92 (1.32–2.78), p<0.001
Grade Moderate/Well differentiated 1.00 1.00
Poor/undifferentiated 1.41 (0.98–2.04), p=0.07 1.40 (0.85–2.31), p=0.19
Lauren’s Intestinal 1.00 1.00
Diffuse 1.24 (0.87–1.76), p=0.23 0.81 (0.50–1.32), p=0.40
Model (2): Factors affecting survival in univariate analysis
Univariate, HR (95% CI), p value Multivariable, HR (95% CI), pvalue
G-INT/G-DIF G-INT 1.00 1.00
G-DIF HR: 1.79, (1.28–2.51), p=0.001 1.63 (1.16–2.29), p=0.005
Gender Male 1.45 (1.01–2.08), p=0.05 1.00 (0.69–1.47), p=0.98
Female 1.00 1.00
Margins Negative 1.00 1.00
Positive 1.83 (1.16–2.90), p=0.01 1.56 (0.98–2.49), p=0.06
Stage Stage 1 1.00
Stage 2 4.40 (1.49–12.99), p=0.01 4.39 (1.48–12.97), p=0.01
Stage 3 11.99 (4.35–33.04), p<0.001 12.29 (4.45–33.98), p<0.001
Stage 4 30.13 (10.78–84.22), p<0.001 28.56 (10.14–80.43), p<0.001
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Table 3
Interaction between the G-INT and G-DIF subtypes and benefit from 5-FU based adjuvant treatment.Cox
proportional hazards regression for survival was used to evaluate interactions between the intrinsic subtypes
and 5-FU adjuvant treatment, in patients eligible for adjuvant 5-FU based therapy. Hazard ratios are adjusted
for stage.
G-INT (deaths/N) G-DIF (deaths/N)
HR (95%CI), p value (G-INT:
HR=1.0)
p value for
interaction
Adjuvant 5-FU based-
treatment
20/45 (44%) 29/38 (76%) 2.71 (1.52–4.85), p=0.001
P=0.002Surgery alone 49/136 (36%) 48/86 (56%) 1.37 (0.92 – 2.05), p=0.12
HR (95%CI), p value (5-
FU based therapy, HR=1)
1.68 (0.98–2.88), p=0.06 0.90 (0.56–1.45), p=0.67
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